GETT
19.4.2021 15:02:06 CEST | Business Wire | Press release
Gett, the leading innovator in corporate Ground Transportation Management (GTM), continues to expand its marketplace of global partner fleets onto one technology platform to provide broad geographic coverage and service levels for enterprise clients.
Gett launched one of the first-ever on-demand corporate travel services in 2010, attracting Google and Disney among its first clients. With over 10 years of expertise designing seamless ground transportation experiences, Gett reduces corporate spend on ground transportation for its clients by up to 45% by offering price comparison, enforcement of travel policy compliance and optimization of back-office processes. Gett’s platform also provides other benefits, including a seamless rider experience for employers prioritizing the safety and security of their people returning to business travel following Covid-19 lockdown.
The expansion of Gett’s global platform coincides with a new supply partnership, as US taxi and e-fleet operator Curb Mobility partners with Gett and joins a portfolio of operating fleets including Lyft and Ola to access incremental high quality demand. This partnership will enable Gett to extend its presence to 65 cities in the US, expanding Gett’s marketplace to include yellow cabs as well as Gett’s existing range of vehicles and partner fleets. Bringing corporate customers a range of licensed vehicles, this new partnership supports increased demand for ground transportation as business professionals seek enhanced safety in light of the Covid-19 pandemic with the resumption of business travel.
Partner fleets already accounted for approximately one-third of B2B rides taken on Gett in Q1 2021. With the addition of Curb, and momentum in Gett’s transition from ride-hailing to an enterprise marketplace software platform, it is expected that partner fleets will represent the majority of Gett’s B2B rides globally by the end of 2021.
Gett’s largest markets are becoming lead indicators for the ground transportation and global corporate travel industries, with the progress of Covid-19 vaccination programmes in Israel and the UK. In Q1 2021, global transactions on Gett’s platform by corporate users returned to approximately 80% of the volumes seen for the corresponding period in 2020 ahead of Covid-19 lockdown restrictions. In this time period, individual markets also experienced corporate passenger volumes in excess of 2020 peaks.
Dave Waiser, CEO and co-founder of Gett commented : “Today’s partnership cements Gett’s position as a technology platform focused on corporate Ground Transportation Management (GTM), where spend is worth $79.6B globally. In recent years, we have become the GTM category leader, serving over a quarter of Fortune 500 companies.
“Our cloud-based software aggregates existing transportation providers into a single platform, helping businesses effectively manage all of their ground transportation spend. Additionally, it can expand companies’ coverage and reach by connecting them to a global transportation grid.
“We believe that bringing corporate fleets and ride-hailing companies together on one platform, optimising the entire employee experience, from booking and riding to invoicing and analytics, saves corporations both time and money.”
Amos Tamam, CEO at Curb commented : “As cities across the U.S. prepare for the return of international travel, our partnership with Gett will create new income opportunities for local drivers and ensure Gett's business users have access to the same safe, reliable transportation options trusted by locals. By integrating with platforms like Gett, we're aiming to make taxis more ubiquitous online by opening up new digital avenues for today’s consumers and businesses to find and book taxis.”
ENDS
View source version on businesswire.com: https://www.businesswire.com/news/home/20210419005037/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press release
The project confirms NHOA Energy’s long-term commitment to the Italian market NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
Andersen Consulting udvider sine kompetencer inden for ledelsesrekruttering med Lansdowne Executive Search18.2.2026 17:08:00 CET | Pressemeddelelse
Andersen Consulting styrker sin humancapital-praksis gennem en samarbejdsaftale med Lansdowne Executive Search, der er en Dublin-baseret virksomhed med speciale i lederrekruttering, midlertidige ledelser og bestyrelsesudnævnelser. Lansdowne Executive Search er en irisk-ejet virksomhed, der blev grundlagt i 2015, og som tilbyder C-level-ledelsesekruttering, deltidsledere og bestyrelsesplaceringer. Som en partnerdrevet boutique-virksomhed er Lansdowne kendt for, at seniorledelsen er tæt involveret i alle kundeprojekter. Virksomheden hjælper kunder med at navigere i komplekse ledelsesovergange og vækststrategier på tværs af en bred vifte af sektorer, herunder finans, byggeindustrien, nonprofit, landbrug, videregående uddannelse, den offentlige sektor samt teknologi, medier og telekommunikation. "God ledelse er afhænger af situationen, og det kræver forståelse af langt mere end blot et CV," sagde Tom Keane, der er partner hos Lansdowne Executive Search. "Samarbejdet med Andersen Consulting
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom